Brain and whole-body fdg-pet in diagnosis, treatment monitoring and long-term follow-up of primary cns lymphoma

Radiology and Oncology

Volumn 47, Issue 2, 2013, Pages 103-110

  Maza, Sofiane ^a   Buchert, Ralph ^b   Brenner, Winfried ^b   Munz, Dieter Ludwig ^b   Thiel, Eckhard ^c   Korfel, Agnieszka ^c   Kiewe, Philipp ^c  

^a Hospital Vivantes Spandau   (Germany)

^b Department of Nuclear Medicine ^*  (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Imaging; Pet ct; Primary central nervous system lymphoma; Response assessment

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BONE MARROW BIOPSY; BRAIN DAMAGE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CEREBELLUM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMAGE RECONSTRUCTION; IMMUNOCOMPROMISED PATIENT; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROSPECTIVE STUDY; SPINAL CORD VENTRAL HORN; STEREOTACTIC BIOPSY; THALAMUS; TREATMENT RESPONSE; WHOLE BODY PET;

EID: 84884990492     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2013-0016     Document Type: Article

References (16)

1. Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y. Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor. Nucl Med Commun 2009; 30:602-9.
2. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STDAIDS 1996; 7:337-46. (Pubitemid 26330308)
3. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995; 123:594-8.
4. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22:360-71. (Pubitemid 17074568)
5. Kuwabara Y, Ichiya Y, Otsuka M, Miyake Y, Gunasekera R, Hasuo K, et al. High [18FJFDG uptake in primary cerebral lymphoma: a PET study. J Comput Assist Tomogr 1988;12:47-8. (Pubitemid 18036654)
6. Mohile NA, Deangelis LM, Abrey IE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10:223-8.
7. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6:818-20, 840.
8. Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 2010; 24:335-43.
9. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Bur J Nucl Med Mol Imaging 2006; 33:164-8. (Pubitemid 43152883)
10. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine- 18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33:532-6.
11. Karantanis D, O'Eill B P, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV- negative patients. Nucl Med Commun 2007; 28:834-41. (Pubitemid 47494107)
12. Karantanis D, O'Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med 2007; 32:271-4. (Pubitemid 46569310)
13. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 2007; 34:78-86. (Pubitemid 44885557)
14. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034-43. (Pubitemid 46224010)
15. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008; 112:1812-20. (Pubitemid 351536842)
16. Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brucher J, et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128:177-83.